The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Treatment of cytokine-induced depression
Abstract
A high proportion of cancer and hepatitis C patients who receive cytokine immunotherapy develop symptoms of depression that are indistinguishable from those found in major depressive disorders. These symptoms are alleviated by anti-depressant treatment. Moreover, preventive treatment with anti-depressants, in particular selective serotonin reuptake inhibitors (SSRIs) attenuates IFN-alpha-associated symptoms of depression, anxiety, and neurotoxicity. The intermediate mechanisms of these effects are still unclear. Studies suggest that the state of depression is associated with an increase in plasma levels of various cytokines and soluble cytokine receptors. Furthermore, anti-depressants have been shown to shift the cytokine network towards a decreased production of pro-inflammatory cytokines and an increased production of anti-inflammatory cytokines. Other studies suggest that anti-depressants can also modify immune reactivity by acting on neural structures involved in neuroimmunomodulation. It is possible that anti-depressants could help to normalize the serotoninergic neurotransmission that is likely disrupted during immunotherapy due to the potent effects of cytokines on the metabolism of the amino acid precursor tryptophan. Further work is needed to optimize strategies for preventing neuropsychiatric side effects of cytokine immunotherapy, to clarify the mechanisms involved in the alleviating effects of anti-depressants on cytokine-induced depression, as well as to assess the possible consequences of anti-depressant therapy on the efficacy of immunotherapy on the disease process.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Additional evidence contributing to neuroimmune theories of depression and anxiety arise from observations that inflammatory interventions can lead to symptoms of these disorders, such as in the case of patients receiving interferon (IFN) alpha treatment [64].”
From The menace of obesity to depression and anxiety prevalence (2022) · cites this paper as [64]
Citations
Cites
Kirkwood, J. M., Strawderman, M. H., Ernstoff, M. S., Smith, T. J., Borden, E. C., & Blum, R. H. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.1.7 · Cited by 2,089
Paroxetine for the prevention of depression induced by high-dose interferon alfa.
Musselman, D. L., Lawson, D. H., Gumnick, J. F., Manatunga, A. K., Penna, S., Goodkin, R. S., Greiner, K., Nemeroff, C. B., & Miller, A. H. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103293441303 · Cited by 1,120
Capuron, L. (2002) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00407-9 · Cited by 797
Capuron, L., Ravaud, A., Neveu, P. J., Miller, A. H., Maes, M., & Dantzer, R. (2002) · Molecular Psychiatry · doi:10.1038/sj.mp.4000995 · Cited by 473
Self-citationThe Neuropsychiatric Effects of Treatment with Interleukin-2 and Lymphokine-Activated Killer Cells
Denicoff, K. D., RUBINOW, D. R., PAPA, M. Z., SIMPSON, C., SEIPP, C. A., LOTZE, M. T., Chang, A. E., ROSENSTEIN, D., & Rosenberg, S. A. (1987) · Annals of Internal Medicine · doi:10.7326/0003-4819-107-2-293 · Cited by 456
Maes, M. H. J., Scharpé, S., Meltzer, H. Y., Bosmans, E., Suy, E., Calabrese, J. R., & Cosyns, P. R. (1993) · Psychiatry Research · doi:10.1016/0165-1781(93)90027-e · Cited by 441
Haack, M., Hinze‐Selch, D., Fenzel, T., Kraus, T., Kühn, M., Schuld, A., & Pollmächer, T. (1999) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(99)00021-7 · Cited by 329
Mood and cognitive side effects of interferon-alpha therapy.
Valentine, A. D., Meyers, C. A., Kling, M. A., Richelson, E., & Hauser, P. (1998) · PubMed · Cited by 312
Maes, M., Bosmans, E., Suy, E., Vandervorst, C., DeJonckheere, C., & Raus, J. (1991) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1991.tb03163.x · Cited by 268
Cytokine Production and Serum Proteins in Depression
SEIDEL, A., AROLT, V., HUNSTIGER, M., RINK, L., BEHNISCH, A., & KIRCHNER, H. (1995) · Scandinavian Journal of Immunology · doi:10.1111/j.1365-3083.1995.tb03604.x · Cited by 244
Research works printed but not linked: 2
- Gumnick, 2001, The effects of paroxetine on interferon-α-induced neuropsychiatric and physical symptoms in patients witn malignant melanoma, Brain Behav. Immun., 15, 116
- Schuld, 2000, Plasma levels of cytokines and soluble cytokine receptors during treatment with olanzapine, Schizophr. Res., 43, 154
Cited by
Sorted by citations
Cytokines and major depression
Schiepers, O. J. G., Wichers, M. C., & Maes, M. (2005) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2004.11.003 · Cited by 1,235
The Semantics of Microglia Activation: Neuroinflammation, Homeostasis, and Stress
Woodburn, S. C., Bollinger, J. L., & Wohleb, E. S. (2021) · Journal of Neuroinflammation · doi:10.1186/s12974-021-02309-6 · Cited by 783
The kynurenine pathway: a finger in every pie
Savitz, J. B. (2019) · Molecular Psychiatry · doi:10.1038/s41380-019-0414-4 · Cited by 805
Major depression after breast cancer: a review of epidemiology and treatment
Fann, J. R., Thomas-Rich, A. M., Katon, W. J., Cowley, D., Pepping, M., McGregor, B. A., & Gralow, J. (2008) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2007.10.008 · Cited by 586
Inflammation Effects on Motivation and Motor Activity: Role of Dopamine
Felger, J. C., & Treadway, M. T. (2016) · Neuropsychopharmacology · doi:10.1038/npp.2016.143 · Cited by 471
Metadata
- Authors
- Capuron, L., Hauser, P., Hinze-Selch, D., Miller, A. H., & Neveu, P. J.
- Affiliations
- Emory University (US)
- Université de Bordeaux (FR)
- Corresponding author
- Neveu, Pierre J
- ORCID
- Capuron, Lucile
- Venue
- Brain Behavior and Immunity
- Publisher
- Elsevier BV
- Published
- 2002-10
- Volume
- 16
- Issue
- 5
- Pages
- 575-580
- ISSN
- 0889-1591 (ISSN-L)
- OpenAlex
- W2002423129
- Cited by
- 132
- References
- 30
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 2 · 2023: 4 · 2022: 5 · 2021: 9 · 2020: 6 · 2019: 6 · 2018: 9 · 2017: 7 · 2016: 7 · 2015: 5 · 2014: 4 · 2013: 6 · 2012: 4
- FWCI
- 0.66
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Brain Behavior and Immunity (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Topics
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Behavioral Neuroscience › Stress Responses and Cortisol
- Keywords
- cytokine therapy, antidepressants, selective serotonin reuptake inhibitors, interferon-alpha, cancer patients, hepatitis C, neurotoxicity, anxiety, neuroimmunomodulation, serotonergic neurotransmission, tryptophan metabolism, inflammatory cytokines, anti-inflammatory cytokines, soluble cytokine receptors, neuropsychiatric adverse effects
- MeSH terms
- Antidepressive Agents, Depressive Disorder, Humans, Immunotherapy, Serotonin, Sleep, Tryptophan, Cytokines, Receptors, Cytokine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
